Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Velinova

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Expert Opinion on Biological Therapy|January 31, 2019
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methodsOliver von Richter, Lena Lemke, Halimuniyazi Haliduola, et al.
Antiviral Therapy|August 22, 2013
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovirMarc Bifano, Carey Hwang, Berend Oosterhuis, et al.
British Journal of Clinical Pharmacology|October 30, 2016
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringesOliver von Richter, Andrej Skerjanec, Miguel Afonso, et al.
British Journal of Clinical Pharmacology|July 28, 2025
Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2α inhibitor, in healthy participantsMohammad Ghasemi, Ji Yun Kim, Lisa Seitz, et al.
Clinical and Translational Science|May 18, 2024
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitorEwa Gatlik, Beata Mehes, Emilie Voltz, et al.
British Journal of Clinical Pharmacology|July 1, 2018
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjectsFrank Schneider, Lavi Erisson, Hooman Beygi, et al.
British Journal of Clinical Pharmacology|February 6, 2020
A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologicsAnne Bellon, Jessie Wang, Andrej Skerjanec, et al.
Nature Communications|May 15, 2021
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|April 16, 2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|February 5, 2024
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Expert Opinion on Biological Therapy|January 31, 2019
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methodsOliver von Richter, Lena Lemke, Halimuniyazi Haliduola, et al.
Antiviral Therapy|August 22, 2013
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovirMarc Bifano, Carey Hwang, Berend Oosterhuis, et al.
British Journal of Clinical Pharmacology|October 30, 2016
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringesOliver von Richter, Andrej Skerjanec, Miguel Afonso, et al.
British Journal of Clinical Pharmacology|July 28, 2025
Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2α inhibitor, in healthy participantsMohammad Ghasemi, Ji Yun Kim, Lisa Seitz, et al.
Clinical and Translational Science|May 18, 2024
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitorEwa Gatlik, Beata Mehes, Emilie Voltz, et al.
British Journal of Clinical Pharmacology|July 1, 2018
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjectsFrank Schneider, Lavi Erisson, Hooman Beygi, et al.
British Journal of Clinical Pharmacology|February 6, 2020
A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologicsAnne Bellon, Jessie Wang, Andrej Skerjanec, et al.
Nature Communications|May 15, 2021
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|April 16, 2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|February 5, 2024
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Pageof 2